N. Mohammed

1.5k total citations · 1 hit paper
28 papers, 977 citations indexed

About

N. Mohammed is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, N. Mohammed has authored 28 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in N. Mohammed's work include Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (6 papers). N. Mohammed is often cited by papers focused on Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (6 papers). N. Mohammed collaborates with scholars based in United Kingdom, Spain and Belgium. N. Mohammed's co-authors include Susan Harden, Derek Grose, C. Porteous, Ewan MacDermid, Michael R. MacDonald, M. Snee, Corinne Faivre‐Finn, Mary O’Brien, R. McMenemin and Felipe Cardenal and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Lancet Oncology.

In The Last Decade

N. Mohammed

25 papers receiving 968 citations

Hit Papers

Concurrent once-daily versus twice-daily chemoradiotherap... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
    2017 354 citations Corinne Faivre‐Finn, M. Snee et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Mohammed United Kingdom 10 547 354 315 274 212 28 977
Xingsheng Hu China 18 635 1.2× 602 1.7× 285 0.9× 174 0.6× 182 0.9× 100 1.0k
William B. Fisher United States 17 760 1.4× 846 2.4× 212 0.7× 160 0.6× 69 0.3× 39 1.2k
Daphne W. Dumoulin Netherlands 14 948 1.7× 583 1.6× 132 0.4× 99 0.4× 128 0.6× 44 1.3k
Johanna N. Spaans Canada 14 277 0.5× 342 1.0× 144 0.5× 140 0.5× 83 0.4× 35 844
Helge Bischoff Germany 21 873 1.6× 986 2.8× 203 0.6× 336 1.2× 150 0.7× 62 1.6k
Judith Fine United States 16 648 1.2× 584 1.6× 184 0.6× 167 0.6× 75 0.4× 24 1.3k
A. Viúdez Spain 16 503 0.9× 271 0.8× 91 0.3× 180 0.7× 94 0.4× 53 887
Hubert de Crémoux France 19 410 0.7× 806 2.3× 168 0.5× 204 0.7× 88 0.4× 48 1.2k
Ahmed Salem Jordan 19 280 0.5× 438 1.2× 175 0.6× 134 0.5× 218 1.0× 97 1.1k
Amita Maheshwari India 19 429 0.8× 215 0.6× 202 0.6× 474 1.7× 113 0.5× 115 1.5k

Countries citing papers authored by N. Mohammed

Since Specialization
Citations

This map shows the geographic impact of N. Mohammed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Mohammed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Mohammed more than expected).

Fields of papers citing papers by N. Mohammed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Mohammed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Mohammed. The network helps show where N. Mohammed may publish in the future.

Co-authorship network of co-authors of N. Mohammed

This figure shows the co-authorship network connecting the top 25 collaborators of N. Mohammed. A scholar is included among the top collaborators of N. Mohammed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Mohammed. N. Mohammed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Abbas, Ahmed M., et al.. (2025). Determination of reference intervals for common liver function tests among healthy adults. Scientific Reports. 15(1). 12896–12896. 1 indexed citations
3.
Wijsman, Robin, Yoran M. Hummel, N. Mohammed, et al.. (2020). Thoracic radiotherapy decreases right ventricle function : first results of the CLARIFY study. Radiotherapy and Oncology. 152. 1 indexed citations
4.
Graham, Janet S., Wendy Campbell, Nicholas MacLeod, et al.. (2020). Prospective DPYD testing and dose adjustment in colorectal cancer patients prior to fluoropyrimidine-based chemotherapy: Experience in a regional cancer center.. Journal of Clinical Oncology. 38(4_suppl). 93–93. 1 indexed citations
5.
Mohammed, N., et al.. (2020). Myocardial Functional Disorders In Hemodialysis Patient With Intradialytic Hypertention. Benha Medical Journal. 37(1). 0–0.
6.
Manoharan, Prakash, Ahmed Salem, Hitesh Mistry, et al.. (2019). 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial. Journal of Thoracic Oncology. 14(7). 1296–1305. 20 indexed citations
7.
Mohammed, N., et al.. (2019). EP-1338 Hypofractionated Chemoradiotherapy for stage-3 Non-small cell Lung cancer-Single centre experience. Radiotherapy and Oncology. 133. S733–S733.
8.
Lester, J.F., Chinnamani Eswar, N. Mohammed, et al.. (2018). Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC.. Journal of Clinical Oncology. 36(15_suppl). e20551–e20551. 1 indexed citations
9.
Salem, Ahmed, Hitesh Mistry, Susan Harden, et al.. (2018). OA13.01 The Impact of [18F]fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial. Journal of Thoracic Oncology. 13(10). S351–S351. 1 indexed citations
10.
Faivre‐Finn, Corinne, M. Snee, Linda Ashcroft, et al.. (2017). Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology. 18(8). 1116–1125. 354 indexed citations breakdown →
11.
12.
Din, Omar, Susan Harden, Emma Hudson, et al.. (2013). Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: Results from 4 UK centres. Radiotherapy and Oncology. 109(1). 8–12. 57 indexed citations
13.
Price, Allan, Ann Yellowlees, Catriona Keerie, et al.. (2012). Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. Lung Cancer. 77(3). 532–536. 8 indexed citations
14.
Yumuk, Perran Fulden, et al.. (2012). How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? – A short report. European Journal of Cancer. 48(14). 2163–2165. 11 indexed citations
15.
Rodríguez, María E., Marta Compte, Elisa Cisneros, et al.. (2011). Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes and Cancer. 51(4). 409–418. 249 indexed citations
16.
Mohammed, N., María E. Rodríguez, J.M. Jurado, et al.. (2011). EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages. Oncology Letters. 2(4). 719–724. 23 indexed citations
17.
Price, Allan, Ann Yellowlees, Corinne Faivre‐Finn, et al.. (2009). A randomised trial of radical radiotherapy with or without low dose gemcitabine in medically inoperable patients with T1-2 N0-1 M0 non-small cell lung cancer (NSCLC). Research Explorer (The University of Manchester). 4(9). 1 indexed citations
18.
MacDermid, Ewan, et al.. (2008). Improving patient survival with the colorectal cancer multi‐disciplinary team. Colorectal Disease. 11(3). 291–295. 154 indexed citations
19.
Cassidy, J, et al.. (2007). A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiences. European Journal of Oncology Nursing. 11(3). 247–254. 31 indexed citations
20.
Mohammed, N. & N. O’Rourke. (2000). Changing practice in the radiation treatment of non-Hodgkin's lymphoma. Journal of Radiotherapy in Practice. 2(3). 133–138. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xingsheng Hu Breakdown of academic impact, for papers by William B. Fisher Breakdown of academic impact, for papers by Daphne W. Dumoulin Breakdown of academic impact, for papers by Johanna N. Spaans Breakdown of academic impact, for papers by Helge Bischoff Breakdown of academic impact, for papers by Judith Fine Breakdown of academic impact, for papers by A. Viúdez Breakdown of academic impact, for papers by Hubert de Crémoux Breakdown of academic impact, for papers by Ahmed Salem Breakdown of academic impact, for papers by Amita Maheshwari
Rankless by CCL
2026